Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial by Sas, T.C.J. (Theo) et al.
Normalization of Height in Girls with Turner Syndrome
after Long-Term Growth Hormone Treatment: Results of
a Randomized Dose-Response Trial*
THEO C. J. SAS, SABINE M. P. F. DE MUINCK KEIZER-SCHRAMA,
THEO STIJNEN, MAARTEN JANSEN, BARTO J. OTTEN,
J. J. GERA HOORWEG-NIJMAN, THOMAS VULSMA, GUY G. MASSA,
CATRIENUS W. ROUWE´, H. MAARTEN REESER, WILLEM-JAN GERVER,
JOS J. GOSEN, CISKA RONGEN-WESTERLAKEN, AND STENVERT L. S. DROP
Department of Pediatrics, Division of Endocrinology (T.C.J.S., S.M.P.F.d.M.K-S., S.L.S.D.) Sophia
Children’s Hospital, 3015 GJ Rotterdam; Department of Epidemiology and Biostatistics (T.S.),
Erasmus University Rotterdam, 3015 GJ Rotterdam; Wilhelmina Children’s Hospital (M.J.), 3584 EA
Utrecht; Sint Radboud University Hospital (B.J.O.), 6525 GA Nijmegen; Free University Hospital
(J.J.G.H-N.), 1081 HV Amsterdam; Emma Children’s Hospital, Academic Medical Center (T.V.), 7105
AZ Amsterdam; Medical University Center (G.G.M.), 2333 AA Leiden; Beatrix Children’s Hospital
(C.W.R.), 9713 EZ Groningen; Juliana Children’s Hospital (H.M.R.), 2566 ER The Hague; Academic
Hospital (W.J.G.), 6202 AZ Maastricht; Rijnland Hospital (J.J.G.), 2353 GA Leiderdorp; Canisius-
Wilhelmina Hospital (C.R-W.), 6532 SZ Nijmegen, the Netherlands
ABSTRACT
Short stature and ovarian failure are the main features in Turner
syndrome (TS). To optimize GH and estrogen treatment, we studied
68 previously untreated girls with TS, age 2–11 yr, who were ran-
domly assigned to one of three GH dosage groups: group A, 4 IU/
m2zday ('0.045 mg/kgzday); group B, first yr 4, thereafter 6 IU/m2zday
('0.0675 mg/kg/day); group C, first yr 4, second yr 6, thereafter 8
IU/m2zday ('0.090 mg/kgzday). In the first 4 yr of GH treatment, no
estrogens for pubertal induction were given to the girls. Thereafter,
girls started with 17b-estradiol (5 mg/kg bwzday, orally) when they
had reached the age of 12 yr. Subjects were followed up until attain-
ment of adult height or until cessation of treatment because of sat-
isfaction with the height achieved.
Seven-year data of all girls were evaluated to compare the growth-
promoting effects of three GH dosages during childhood. After 7 yr,
85% of the girls had reached a height within the normal range for
healthy Dutch girls. The 7-yr increment in height SD-score was sig-
nificantly higher in groups B and C than in group A. In addition, we
evaluated the data of 32 of the 68 girls who had completed the trial
after a mean duration of treatment of 7.3 yr (range, 5.0 - 8.75). Mean
(SD) height was 158.8 cm (7.1), 161.0 cm (6.8), and 162.3 cm (6.1) in
groups A, B, and C, respectively. The mean (SD) difference between
predicted adult height before treatment and achieved height was 12.5
cm (2.1), 14.5 cm (4.0), and 16.0 cm (4.1) for groups A, B, and C,
respectively, being significantly different between group A and group
C. GH treatment was well tolerated in all three GH dosage groups.
In conclusion, GH treatment starting in relatively young girls with
TS results in normalization of height during childhood, as well as of
adult height, in most of the individuals. With this GH and estrogen
treatment regimen, most girls with TS can grow and develop much
more in conformity with their healthy peers. (J Clin Endocrinol Metab
84: 4607–4612, 1999)
SHORT STATURE and ovarian failure are the main fea-tures in Turner syndrome (TS). The median adult height
of North European girls with TS is 146.9 cm, being, on av-
erage, approximately 20 cm less than their healthy peers (1,
2). Although these girls are not GH deficient (3), GH admin-
istration accelerates growth in a dose-dependent way (4, 5).
In many countries, TS is an accepted indication for GH treat-
ment, although the effect of GH on adult height is inconsis-
tent (6–11). In most girls with TS, puberty has to be induced
by estrogen therapy. The optimal age to start estrogen ther-
apy is still a point of discussion. It has been suggested to
postpone estrogen therapy to delay closure of the epiphysial
growth plates and, consequently, to prolong the growth
phase (9–12). However, delay of pubertal development may
have serious psychosocial consequences.
To optimize GH and estrogen treatment, in 1989 we started
a randomized dose-response study in 68 girls with TS. Four-
year results were described earlier (5). We now report 7-yr
results to compare the long-term growth-promoting effect of
GH in childhood between the three dosage groups. In ad-
dition, growth data of the girls who had completed the trial
before the end of August 1998 have been evaluated.
Patients and Methods
Study subjects
Sixty-eight previously untreated girls with TS were enrolled in a
multicenter GH dose-response study. The diagnosis was confirmed by
lymphocyte chromosomal analysis. Three girls had a prenatal diagnosis.
Inclusion criteria were a chronological age (CA) between 2 and 11 yr,
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height below the 50th percentile for healthy Dutch girls (13), and normal
thyroid function. Exclusion criteria were: associated endocrine and/or
metabolic disorders; growth failure caused by other disorders or emo-
tional deprivation; hydrocephalus; previous use of drugs, which could
interfere with GH treatment; and spontaneous puberty (14). Written
informed consent was obtained from the parents or custodians, whereas
a written assent was obtained in the girls more than 12 yr of age. The
study protocol was approved by the ethics committee of each partici-
pating center.
Study design
After stratification for CA and height sd-score for CA girls were
randomly assigned to one of three GH dosage groups: A, (n 5 23)
receiving 4 IU/m2 body surfacezday (equivalent to 0.045 mg/kg); B, (n 5
23) receiving 4 IU/m2zday in the first yr, followed by 6 IU/m2zday
('0.0675 mg/kgzday); or C (n 5 22) receiving 4 IU/m2zday in the first
yr, 6 IU/m2zday in the second yr, and thereafter 8 IU/m2zday ('0.090
mg/kgzday).
Biosynthetic human GH (Norditropin, Novo Nordisk A/S, Bags-
vaerd, Denmark) was given sc once daily at bedtime using a pen in-
jection system. Every 3 months, the total GH dose was adjusted to the
calculated body surface. According to the study protocol, the GH treat-
ment was stopped when subjects had grown less than 1 cm over 6
months. However, when girls were satisfied with their height achieved,
they elected to stop GH treatment before study criteria for the termi-
nation of treatment had been reached. In the first 4 yr of GH treatment,
no estrogens for pubertal induction were given to the girls. After 4 yr
of GH treatment, estrogen therapy was started in the girls who were
older than 12.0 yr of age; the younger girls started estrogen therapy at
a yearly visit after reaching the age of 12 yr. 17b-Estradiol, 5 mg/kg body
weightzday, orally, were given in the first 2 yr, 7.5 mg/kgzday in the third
yr, and 10 mg/kgzday thereafter. Cyclic progestagen therapy (Duphaston
5 mg/day in the first 14 days of the month) was added after 2 yr of
estrogen therapy. If puberty had developed spontaneously (Tanner
breast stage $2) during the study period and before start of estrogens,
no estrogens were given.
Height was measured at baseline and subsequently every 3 months
using a Harpenden stadiometer. Four measurements per visit were
made by two trained observers (A.v.T. and, subsequently T. Sas), and
the mean was used for the analysis. For the adult height evaluation, adult
height was defined as the most recent available height after discontin-
uation of GH treatment. Height was expressed as sd-score using the
references for healthy Dutch girls (13) or the references for North Eu-
ropean untreated girls with TS (2). At adult height, the height sd-score
for TS was calculated using the reference data of 21 yr of age. Target
height was adapted from Dutch reference data with the addition of 3 cm
for secular trend: TH 5 1⁄2 3 (Hmother 1 Hfather 2 12 cm) 1 3 cm (13).
Target range was defined as the TH 6 8 cm (15). During GH treatment
pubertal stages were assessed according to Tanner (14). Bone age was
determined by the same two observers according to the Tanner and
Whitehouse radius, ulna, short-bones score (16). Bone maturation was
expressed as the ratio of the change in BA to the change in CA (çBA/çCA). Predicted adult height was calculated with the modified pro-
jected adult height method, using the equation of Lyon, adapted to
North European untreated girls with TS (2, 17, 18). To assess the gain in
adult height, the attained adult height was compared with the modified
projected adult height before treatment. Blood samples were taken at the
start of the study and subsequently every yr for determination of the
glycosylated hemoglobin.
Statistical analysis
Results were expressed as mean (sd), unless indicated otherwise.
Differences between the dosage groups were first tested by a linear trend
test. In case of a significant result, this was followed by comparisons with
Student’s t tests. Differences between points in time were tested by
paired Student’s t tests.
Results
Clinical data and 7-yr results
The trial started in November 1989. During the first 3 yr,
three girls, one in each dosage group, dropped out of the
study because of noncompliance and were lost to follow-up.
In October 1997, the remaining 65 girls had been followed for
7 yr. Table 1 lists the baseline clinical data of these girls. The
three dosage groups had similar initial characteristics.
Fig. 1 shows the individual heights of the 65 girls at the
start of GH treatment, as well as after 7 yr. Twelve girls had
completed the trial during the 7-yr study period. After 7 yr
of GH treatment, 55 of the 65 girls (85%) had a height within
the normal range for healthy Dutch girls, whereas only 10
girls (15%) had a height just below the 3rd percentile. Fig. 2
shows the height sd-score of the 65 girls using references of
healthy Dutch girls (bottom) and the height sd-score using
Turner references (top) during the 7-yr study period. At base-
line, the girls in all three groups have a mean height that is
normal for untreated North European girls with TS. After 7
yr of GH treatment, the Turner height sd-score in all three
groups has increased significantly (P , 0.001). The change in
sd-score was significantly higher in groups B and C com-
pared with group A [95% confidence interval (CI): 0.08, 0.95;
P 5 0.02 and 95% CI: 0.38, 1.27; P 5 0.001, respectively].
However, the difference in sd-score between groups B and
C was not statistically significant (95% CI: -0.19, 0.81, P 5
0.22). The height after 7 yr was 16.5 cm (3.5) in group A, 19.6
cm (4.5) in group B, and 21.2 cm (4.3) in group C, greater than
the expected height assuming that these girls would follow
their height percentile when they were not treated with GH.
Compared with healthy Dutch girls, the mean baseline
height of the girls was far below normal (Fig. 2, bottom). After
TABLE 1. Mean (SD) baseline data for each treatment group. Karyotype (45,X; other) is expressed in numbers (percentage) of patients
Group A Group B Group C
Number of girls 22 22 21
Baseline CA (yr) 6.1 (2.1) 6.7 (2.4) 6.5 (2.4)
Baseline bone age (yr) 5.5 (2.2) 6.0 (2.5) 5.8 (2.4)
Baseline SD-score for height
(references healthy
Dutch girls)
22.7 (0.9) 22.4 (1.0) 22.6 (1.0)
Baseline SD-score for height
(references girls with TS)
0.06 (1.03) 0.42 (1.05) 0.18 (1.06)
Baseline modified projected
adult height (cm)
146.0 (5.5) 147.9 (5.6) 146.6 (5.6)
Target height (cm) 168.8 (6.3) 170.1 (6.1) 169.5 (5.6)
Karyotype: 45,X 18 (82%) 21 (96%) 16 (76%)
Karyotype: other 4 (18%) 1 (4%) 5 (24%)
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7 yr, the mean height sd-score in all three groups had in-
creased to values within the normal range for healthy girls.
To compare skeletal maturation during 7 yr of GH treat-
ment between the three GH dosage groups, one can deter-
mine the bone maturation of all girls still receiving GH treat-
ment. However, to avoid selection bias, only girls with a CA
less than or equal to 14 yr after 7 yr of GH treatment were
included in this analysis (groups A, B, and C, n 5 12, 11, 12,
respectively). The mean ratio ç bone age (yr)/çCA (yr) over
7 yr of GH treatment was 1.17 (0.14), 1.24 (0.16), and 1.20
(0.14) in groups A, B, and C, respectively, being significantly
higher than 1 (P , 0.005 for all three GH dosage groups).
These data indicate an acceleration of bone maturation com-
pared with healthy children. However, no significant differ-
ences in bone maturation were found between the three GH
dosage groups.
After 7 yr of GH treatment, 35 girls had started estrogen
therapy at a mean (sd) CA of 12.9 yr (0.8) and a bone age of
13.2 yr (0.6). Twelve of the 35 girls started estrogen therapy
between the CA of 13 and 15 yr because in the first 4-yr study
period no estrogens were given, even if these girls were older
than 12 yr of age. The other 23 of the 35 girls started estrogen
therapy after reaching the age of 12 yr. The distribution of the
35 girls over the Tanner breast stages was: 11 girls were M2,
14 girls were M3, 6 girls were M4, and 4 girls were M5 after
a mean (sd) duration of estrogen therapy of 1.8 yr (0.8). Five
girls did not receive estrogens because of starting sponta-
neous puberty during GH treatment (at the end of the 7-yr
study period, one girl had Tanner breast stage M2, two girls
had M3, one girl had M4, and one girl had M5).
Adult height results
At the end of August 1998, 32 of the 65 girls (groups A, B,
and C, n 5 10, 10, 12, respectively) had completed the study
after a mean duration of treatment of 7.3 yr (1.1) (range, 5.0
2 8.75). Twenty girls had discontinued GH treatment be-
cause of a height velocity less than 1 cm over 6 months,
whereas 12 girls stopped GH treatment because they were
satisfied with their attained height. Table 2 lists the clinical
data of these 32 patients. Except for age, the baseline clinical
data of these 32 girls were comparable with the baseline data
of the 65 girls. Mean height was 158.8 cm (sd 7.1; range,
FIG. 1. Individual heights at the start of the study (E) and after 7 yr of GH treatment (F) in groups A, B, and C, respectively. Twelve girls had
completed the trial during the 7-yr study period (f). Reference curves for healthy Dutch girls (3rd, 10th, 50th, 90th, and 97th percentiles) and
for untreated girls with TS (North European references; 3rd, 50th, and 97th percentiles) are given.
FIG. 2. Height SD-score for CA during 7 yr of GH treatment for groups
A (n 5 22), B (n 5 22), and C (n 5 21), respectively. Top, Height
compared to references for North European girls with TS. Bottom,
Height compared to references for healthy Dutch girls.
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148.3–172.4 cm) in group A, 161.0 cm (sd 6.8; range, 152.8–
176.2 cm) in group B, and 162.3 cm (sd 6.1; range, 154.3–171.2
cm) in group C, respectively. Except one girl, all girls (31 of
32) had a height of more than 150 cm. More than half the girls
(17 of 32) had a height above 160 cm, and five of them
exceeded 170 cm. The mean difference between the target
height and the attained height was 10.9 cm (5.1) for group A,
9.5 cm (4.1) for group B, and 6.7 cm (4.6) for group C. The
target range was reached in 4 of 10 girls in group A, 4 of 10
girls in group B, and 9 of 12 girls in group C. Fig. 3 shows
the attained height of each subject relative to each subject’s
modified projected adult height. The mean increment in
height was 12.5 cm (sd 2.1; range, 7.8–15.7 cm) for group A,
14.5 cm (sd 4.0; range, 8.1–20.3 cm) for group B, and 16.0 cm
(sd 4.1; range, 10.2–24.8 cm) for group C, respectively, being
significantly different from baseline (P , 0.001). The linear
trend test showed a significant positive trend toward a
higher gain in height (equal attained height minus baseline
modified projected adult height) in the dosage groups re-
ceiving a higher GH dose (P 5 0.027). The gain in height was
significantly higher in group C compared with group A (P 5
0.024), but without significant differences between groups A
and B and groups B and C, respectively.
Treatment was well tolerated, and no adverse events were
detected that were considered to be drug related. During the
study period, glycosylated haemoglobin levels remained
within the normal range. In addition, none of the girls de-
veloped diabetes mellitus.
Discussion
This study shows that in girls with TS treatment with
biosynthetic GH, even with the “standard” dose of 4 IU/
m2zday ('0.045 mg/kgzday), results in a normalization of
height during childhood and a normalization of adult height
in most of the girls. The ideal study design to assess the
growth-promoting effect of GH is a randomized controlled
trial with an untreated study group until adult height. Be-
cause at the start of the present study GH treatment in girls
with TS was an accepted indication in the Netherlands, such
a trial was not possible. Therefore, a randomized dose-re-
sponse design was chosen to assess the effect of GH treat-
ment on growth. To determine the effect of GH on adult
height, the attained adult height was compared with the
individually predicted adult height using the modified pro-
jected adult height method based on our own references for
untreated Dutch girls with TS (2, 18). However, in such a
growth analysis, secular trend and errors in adult height
prediction have to be taken into account. Remarkably, the
growth-promoting effect of GH found in the present study
exceeds the effects of secular trend and prediction errors.
After 7 yr of GH treatment, most girls had a height within the
normal range for healthy Dutch girls. In addition, in the 32
girls who had reached adult height, the mean height in the
three dosage groups was approximately 160 cm. Baseline
predicted adult height was exceeded in all subjects, and the
mean gain in adult height was well above 10 cm, even in the
group receiving the standard GH dose of 4 IU/m2zday. More-
FIG. 3. The most recent height of each subject completing GH treat-
ment relative to each subject’s modified projected adult height for
groups A (n 5 10), B (n 5 10), and C (n 5 12), respectively. Mean
increment in height (in cm) relative to modified projected adult height
is indicated.
TABLE 2. Mean (SD) baseline and adult height data in 32 girls who have completed the study
Group A Group B Group C
Number of girls 10 10 12
Baseline age (yr) 7.9 (0.9) 8.6 (1.6) 8.1 (1.4)
Baseline SD-score for height (references healthy Dutch girls) 22.81 (1.17) 22.79 (0.72) 22.84 (0.82)
Baseline SD-score for height (references girls with TS) 0.09 (1.42) 0.17 (0.85) 0.10 (1.01)
Baseline modified projected adult height (cm) 146.2 (7.5) 146.6 (4.5) 146.2 (5.3)
Target height (cm) 169.7 (4.6) 170.5 (5.0) 169.0 (4.5)
Duration GH treatment (months) 93.3 (8.5) 81.3 (14.5) 87.0 (14.8)
Age start 17b-estradiol 12.7 (0.6) 13.3 (1.1) 12.9 (0.8)
Last age (yr) 16.0 (0.8) 15.8 (1.0) 15.7 (0.9)
Last height (cm) 158.8 (7.1) 161.0 (6.8) 162.3 (6.1)
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over, in more than half of the 32 girls, the attained height was
within the target range.
As in the study of Rosenfeld et al. (9), some girls discon-
tinued the GH treatment earlier because they were satisfied
with their attained height. Although the maximal growth-
promoting effect could not be obtained in these girls, such a
precocious termination of GH treatment is the consequence
of the good growth response of the treatment.
The results of the present study contrast with reports stat-
ing that GH treatment in girls with TS results only in modest
increments or have no positive effect at all (6, 19, 20). In these
studies, the age of start of GH treatment was considerably
older than in our study. In the study of Rosenfeld et al. (9),
however, girls were started at a younger age (9.1 yr) and
showed a mean gain in adult height (8.4 cm) being more
comparable with our results. The girls who have reached
adult height in our study had a mean age at baseline of 8.2
yr, being even younger than in the study of Rosenfeld et al
(9). Therefore, in our opinion, the most important reason of
our better results is the fact that GH treatment was started at
a younger age compared to earlier studies. Because the girls
of our study who are still receiving GH are even younger
than the girls who have already attained their adult height,
we expect at least a similar gain in adult height in these
younger girls. To start GH treatment at an appropriate age
to achieve a normal adult height, early diagnosis of TS is very
important. Each physician should consider the diagnosis in
every short girl even when Turner stigmata are absent.
In our view, it is very important for the psychosocial well-
being of the girls to induce the pubertal development in
conformity with their healthy peers. Therefore, in the present
study, estrogen therapy was started at a pubertal age. How-
ever, when estrogen therapy is started before the end of the
growth phase one runs the risk of earlier epiphysial closure,
and consequently a lower gain in adult height. From the
results of the present study we can state that low-dose es-
trogens at a pubertal age does not interfere with the capa-
bility of GH treatment to normalize adult height in most of
the girls with TS. Thus, a major outcome of our study is that
with these GH and estrogen treatment regimens, most girls
with TS can grow and develop much more in conformity
with their healthy peers.
Seven-year data demonstrated a higher increment in
height in the GH dosage groups receiving 6 or 8 IU/m2zday
compared with 4 IU/m2zday. In the 32 girls who had attained
their adult stature, the gain in adult height over the baseline
predicted adult height was higher with a GH dose of 8
compared with 4 IU/m2zday (16.0 vs. 12.5 cm). However, this
difference in gain in adult height is quite small in proportion
to the difference in the GH dose between these two groups.
In contrast, Carel et al. (21) found an increment in adult height
that was twice as high in a study group who received an
increasing GH dose (dependent on the height velocity, up to
9 IU/m2zday) compared to a fixed GH dose (approximately
3.9 IU/m2zday) group (10.6 vs. 5.2 cm). However, these in-
crements in adult height in both study groups were even
lower compared to the results of our dosage group receiving
4 IU/m2zday, probably due to the higher baseline age of the
girls in that study compared to our study.
In conformity with the study of Carel et al. (21) in which
even higher GH dosages were used than in our study, tol-
erance to all three GH regimens was good. Our 4-yr results
of the effects of GH treatment on lipid metabolism showed
no unwanted side effects (22). As described in other studies,
GH treatment had no adverse effect on glucose metabolism,
but the insulin levels had increased significantly after 4 yr of
GH treatment compared to baseline levels (22–24). In the
present study, we showed that during 7 yr of treatment
glycosylated hemoglobin levels stayed within the normal
range; an extensive evaluation of the effects of long-term GH
treatment on carbohydrate metabolism is described else-
where (24a). In a previous paper, we showed that 7 yr of GH
treatment does not have adverse effects on left ventricular
heart dimensions or blood pressure (25).
If higher GH dosages have proven to be safe on the very
long-term and result in a clinically significant higher incre-
ment in adult height compared to lower GH dosages, cost-
benefit evaluations have to be performed. Furthermore, psy-
chological studies are required to evaluate whether the
(early) normalization of height is accompanied by an im-
provement of the psychosocial functioning in childhood as
well as in adulthood.
In conclusion, GH treatment starting in relatively young
girls with TS results in normalization of height during child-
hood and normalization of adult height in most of the girls,
even using the “standard” GH dose of 4 IU/m2zday ('0.045
mg/kgzday), and without unwanted side effects. Higher GH
doses may be more effective, but the efficacy on adult height
and safety in the very long-term have still to be proven.
Induction of puberty with low-dose estrogens can be started
at normal pubertal age without interference with the capa-
bility of GH treatment to normalize adult height in most of
the girls with TS.
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Erratum
In the article “Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH
concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination
rate in healthy young women and men” by N. Shah et al. (The Journal of Clinical Endocrinology & Metabolism
84:2862–2869), the authors make the following correction to the text.
In Subjects and Methods, the i.v. constant GH infusion dose should read 0.5, 1.5, or 4.5 mg/kg/3 hours. The
authors regret the error.
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